Novo, Kallyope link to develop obesity, diabetes therapies

Novo Nordisk and Kallyope are joining forces to discover novel peptide therapeutics for obesity and diabetes.

Under a joint research plan, the companies will work together on ‘in vitro’ and ‘in vivo’ studies to validate a number of product candidates identified via Kallyope’s platform able to interrogate the gut-brain axis, which is known to play a significant role in appetite regulation and energy homoeostasis.

Following validation and option exercise, Novo will then take on responsibility for further preclinical and clinical development, manufacturing and commercialisation.

Kallyope will receive an upfront payment and research support for activities conducted in the collaboration, and a license fee in the event that Novo chooses to exercise an option to a therapeutic discovered and validated in the joint research plan, as well as potential research, development and sales milestones and sales royalties.

"Novo Nordisk is renowned for its expertise in the discovery and development of peptide therapeutics, as well as its commitment to and leadership in therapeutics for obesity and diabetes," said Nancy Thornberry, Kallyope’s chief executive.

"Coupling Novo Nordisk’s formidable capabilities with Kallyope’s unique, sophisticated platform makes for a very attractive strategic collaboration that complements our small molecule focus."